Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 16/20 | 0.47 |
| ▸ | DRD1 | P21728 | 10/20 | 0.47 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039709 | 0.85 | DRD3 (0.63) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL1037156 | 0.84 | DRD3 (0.62) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL10978638 | 0.80 | DRD3 (0.34) | DRD3DRD1DRD2NPC1ALDH1A1 | |
| SCHEMBL9377321 | 0.79 | DRD3 (0.65) | DRD3DRD1DRD2DRD4HTR2A | |
| SCHEMBL6769602 | 0.78 | DRD3 (0.38) | DRD3DRD1DRD2DRD4HTR1A | |
| SCHEMBL6774144 | 0.77 | DRD3 (0.36) | DRD3DRD1DRD2DRD4HTR2A | |
| SCHEMBL7144008 | 0.76 | DRD3 (0.33) | DRD3DRD1DRD2NPC1ALDH1A1 | |
| SCHEMBL6780135 | 0.76 | DRD3 (0.34) | DRD3DRD1DRD2ALDH1A1DRD4 | |
| SCHEMBL9379717 | 0.75 | DRD2 (0.60) | DRD3DRD2HTR1AHTR7 | |
| SCHEMBL9376764 | 0.74 | HTR7 (0.61) | DRD3DRD2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723384-B2 | Keto lactam compounds and use thereof | ABBOTT GMBH & CO. KG. (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1692129-B1 | KETO LACTAM COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-09-20 | — | — | US | disclosed |
| EP-1692129-A1 | KETO LACTAM COMPOUNDS AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056546-A1 | KETO LACTAM COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | OPRD1, DRD3, OPRK1 | DRD3 2/4885DRD1 5/4885DRD2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.